Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Sep 24:8:1311-6.
doi: 10.2147/PPA.S67090. eCollection 2014.

Acceptability of bone antiresorptive therapy among HIV-infected adults at different stages of antiretroviral therapy

Jillian Taras  1 , Gordon Arbess  2 , James Owen  2 , Charlie B Guiang  2 , Darrell H S Tan  3
Affiliations

Acceptability of bone antiresorptive therapy among HIV-infected adults at different stages of antiretroviral therapy

Jillian Taras et al. Patient Prefer Adherence. .

Abstract

Purpose: Both HIV infection and antiretroviral therapy (ART) are associated with significant decreases in bone mineral density (BMD) and increased fracture rates. To prepare for a randomized controlled trial of prophylactic bone antiresorptive therapy during ART initiation, we assessed the acceptability of this strategy, bone health knowledge, and fracture risk among HIV-infected adults.

Methods: HIV-infected adults with no history of osteoporosis were recruited from one tertiary and one primary care HIV clinic. Participants completed a questionnaire and underwent chart review. The primary outcome was the proportion of respondents expressing interest in taking prophylactic bone antiresorptive therapy in conjunction with ART.

Results: Of 112 respondents, 25.0% were ART naïve, 23.2% had been taking ART for ≤1 year, and 51.8% had been taking ART for >1 year. Half (51.9%) indicated interest in taking short-course prophylactic bone antiresorptive therapy; this did not differ by ART status (53.6% among ART-naïve, 51.3% among ART-treated; P=0.84, chi-square test). In exploratory multivariable analysis adjusted for ART status, a greater number of pills taken per day was positively associated with this outcome (adjusted odds ratio [OR] =1.12 per pill, 95% confidence limit [CL] =1.01, 1.25), while male sex was inversely associated (adjusted OR =0.05, 95% CL =0.01, 0.24). Among those willing to take therapy, most (80.4%) were willing to do so for "as long as needed" and preferred weekly dosing (70.9%) to daily dosing (12.7%).

Conclusions: Half of this sample would be willing to take bone antiresorptive therapy together with ART, with preferences for weekly dosing and for whatever duration may be required. These data will inform the design of future trials to protect bone health in HIV.

Keywords: HIV; bone antiresorptive therapy; prophylaxis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flowchart of participants approached and included.
Figure 2
Figure 2
Perceived definitions of fracture risk. Notes: The diamond represents the mean. The circle represents an outlier.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20(17):2165–2174. - PubMed
    1. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008;93(9):3499–3504. - PMC - PubMed
    1. Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26(7):825–831. - PubMed
    1. Young B, Dao CN, Buchacz K, Baker R, Brooks JT, HIV Outpatient Study (HOPS) Investigators Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000–2006. Clin Infect Dis. 2011;52(8):1061–1068. - PubMed
    1. Amorosa V, Tebas P. Bone disease and HIV infection. Clin Infect Dis. 2006;42:108–14. - PubMed

LinkOut - more resources